GH1 and Behcet disease: However, when we concomitantly administered GH and inhibited the action of both receptors VEGFR1 and VEGFR2 (BD + GH + anti-VEGFR1 + anti-VEGFR2), the hepatic damage results were similar to those of the BD group.